Evidence map›Paper›PMID 41668528›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Synergistic Mn-MOF Activation of Pistol Ribozymes for Cancer Immunotherapy.

Ming Zhao, Shan Qiao, Jie Bai, Jingjing Zhang, Zhiqin Xi, Zhenzhen Li, Xuelin Zhan, Ying Zhang, Xiaotong Yu, Yao Chen and 1 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ming ZhaoState Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, China.ORCID https://orcid.org/0009-0008-0214-8144
Shan QiaoState Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, China.
Jie BaiState Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, China.
Jingjing ZhangState Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, China.
Zhiqin XiState Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, China.
Zhenzhen LiChina Regional Research Centre, International Centre for Genetic Engineering and Biotechnology, Taizhou, Jiangsu, P. R. China.
Xuelin ZhanChina Regional Research Centre, International Centre for Genetic Engineering and Biotechnology, Taizhou, Jiangsu, P. R. China.
Ying ZhangSchool of Medicine, University of St Andrews, St Andrews, Fife, UK.
Xiaotong YuState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, P. R. China.
Yao ChenState Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, China.
Yijin LiuState Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, China.ORCID https://orcid.org/0000-0002-3643-8683

Funding

Frontiers Science Center for New Organic Matter, Nankai University 63181206Fundamental Research Funds for the Central Universities 035-63191735Fundamental Research Funds for the Central Universities 035-63221328Haihe Laboratory of Synthetic Biology 22HHSWSS00008Key Project of Tianjin Municipal Natural Science Foundation of China 24ZXZSSS00020Key Project of Tianjin Municipal Natural Science Foundation of China 25ZXZSSS00090National Key Research and Development Program of China 2023YFA0913800National Natural Science Foundation of China 21877065National Natural Science Foundation of China 22371136National Natural Science Foundation of China 32360709National Natural Science Foundation of China 82111530210
6 · The paper itself

Abstract

Checkpoint blockade therapies targeting PD-L1 have revolutionized cancer immunotherapy, yet their efficacy is constrained by systemic immune toxicity and inadequate immune infiltration in certain tumor types. Here, we introduce a synergistic gene-silencing nanosystem based on a target-selective Pistol ribozyme (PS473) encapsulated within a manganese-based, pH-responsive metal-organic framework (NKMOF-101-[Mn]). The engineered PS473 exhibited high cleavage efficiency toward GU-rich PD-L1 mRNA motifs and was further activated by Mn

Indexed as

ImmunotherapyManganeseRNA, CatalyticAnimalsCell Line, TumorHumansMiceMice, Inbred C57BLTumor MicroenvironmentManganeseRNA, Catalyticgene‐targeted therapymanganese ionsmetal−organic frameworks (MOFs)nucleic acid drug deliverypistol ribozyme

Identifiers

PMID41668528
PMCPMC13067846

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.